Garf, wasn't having a go at anyone on this, except perhaps the...

Garf, wasn't having a go at anyone on this, except perhaps the 'excited masses' as you put it - was more a light hearted observation than anything else. [Those masses abound at the speccy end of HC, always have, always will - but of course they are very rarely on the money.] The only similarity between ADO and NEU, that I was hinting at, was those HC expectations, as distinct from their genesis.

As for Neuren, I have no reason to to impugn the expertise and/or integrity of the CEO or board and there is every reason to expect that there MAY be a deal of some form in the pipeline. However, as I see it, no matter how good Dr T is at deal making, if there is a significant disjunct between the companys' view of its risk adjusted value and the view of the industry in general then a decision to 'go it alone' will be the only option.

The answer to that question is obviously evolving (or already evolved) behind closed doors. We simply do not know that answer as yet, but we will, and certainly before the end of 2018.

[By the way, today, at this early stage, there is that 'significant disjunct' between any meaningful buy and sell offers - like 3.01 to 3.39. Perhaps analagous to the situation that the company is in atm?]